Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44237   clinical trials with a EudraCT protocol, of which   7337   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002575-34
    Sponsor's Protocol Code Number:19733
    National Competent Authority:Portugal - INFARMED
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-03-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedPortugal - INFARMED
    A.2EudraCT number2019-002575-34
    A.3Full title of the trial
    A randomized, placebo-controlled, double-blind, parallel-group, multi-center, proof-of concept study to assess the efficacy and safety of BAY 1817080 in patients with overactive bladder (OAB) over a 12-week treatment period.
    Um estudo de prova de conceito, aleatorizado, controlado por placebo, com dupla ocultação, de grupos paralelos e multicêntrico para avaliar a eficácia e segurança do BAY 1817080 em doentes com bexiga hiperativa (BH) ao longo de um período de tratamento de 12 semanas.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study to evaluate the treatment effect and safety of BAY1817080 in patients with overactive bladder (OAB)
    Ensaio clínico para avaliar o tratamento e a segurança de BAY 1817080 em doentes com bexiga hiperativa (BH)
    A.3.2Name or abbreviated title of the trial where available
    Ovader
    Ovader
    A.4.1Sponsor's protocol code number19733
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorBayer AG
    B.1.3.4CountryGermany
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer AG
    B.4.2CountryGermany
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationBayer AG
    B.5.2Functional name of contact pointClinical Trial Contacts
    B.5.3 Address:
    B.5.3.1Street AddressCTP Team / Ref: EU CTR Bayer Pharma AG
    B.5.3.2Town/ cityBerlin
    B.5.3.3Post code13342
    B.5.3.4CountryGermany
    B.5.6E-mailclinical-trials-contact@bayer.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 1817080 25 mg tablets
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEliapixant
    D.3.9.1CAS number n/A
    D.3.9.2Current sponsor codeBAY 1817080
    D.3.9.3Other descriptive nameBAY 1817080
    D.3.9.4EV Substance CodeSUB181864
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBAY 1817080 100 mg tablets
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEliapixant
    D.3.9.1CAS number n/A
    D.3.9.2Current sponsor codeBAY 1817080
    D.3.9.3Other descriptive nameBAY 1817080
    D.3.9.4EV Substance CodeSUB181864
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Overactive bladder
    Bexiga hiperativa
    E.1.1.1Medical condition in easily understood language
    A condition that causes sudden, uncontrolled need or urge to urinate and in some cases may lead to urinary leakage
    Uma condição que causa necessidade súbita e descontrolada de urinar e, em alguns casos, pode levar a perdas urinárias
    E.1.1.2Therapeutic area Diseases [C] - Symptoms and general pathology [C23]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 23.1
    E.1.2Level LLT
    E.1.2Classification code 10059617
    E.1.2Term Overactive bladder
    E.1.2System Organ Class 100000004857
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the efficacy of BAY1817080 125 mg twice a day (BID) in comparison to placebo in the treatment of OAB with urgency urinary incontinence (UUI) over a 12-week treatment period
    Avaliar a eficácia do BAY 1817080 125 mg duas vezes por dia (comprimido) em comparação com o placebo no tratamento de BH com incontinência urinária de urgência (IUU) ao longo de um período de tratamento de 12 semanas.
    E.2.2Secondary objectives of the trial
    To further evaluate the efficacy of BAY1817080 125 mg BID in comparison to placebo in the treatment of OAB with urgency urinary incontinence (UUI) over a 12-week treatment period

    To evaluate the safety and tolerability of BAY1817080 125 mg BID in comparison to placebo over a treatment period of up to 12-weeks
    Avaliar mais aprofundadamente a eficácia do BAY 1817080 125 mg comprimido em comparação com o placebo no tratamento da BH com incontinência urinária de urgência (IUU) ao longo de um período de tratamento de 12 semanas

    Avaliar a segurança e tolerabilidade do BAY 1817080 125 mg comprimido em comparação com o placebo ao longo de período de tratamento até 12 semanas
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Inclusion criteria at screening：
    1. Adults ≥ 18 years of age at the time of signing the informed consent
    2. Have “wet” OAB symptoms (urgency, frequency and urinary incontinence) for ≥ 3 months prior to screening visit
    3. Women of childbearing potential (WOCBP) must agree to use acceptable effective or highly effective contraceptive methods
    4. Capable of giving signed informed consent
    5. Willing and able to complete the electronic bladder diary and questionnaires

    Inclusion criteria at baseline (to be checked at V3, prior to randomization):
    6. Completion of all 3 days of 3-day electronic bladder diary during run-in phase
    7. Compliance of ≥80% with intake of study intervention during run-in
    8. Frequency of micturition on average ≥ 8 episodes/24 hours during the run-in phase according to 3-day electronic bladder diary
    9. Frequency of urgency urinary incontinence on average ≥ 1 episode/24 hours during the run-in phase according to 3-day electronic bladder diary
    Critérios de Inclusão na Triagem:
    1. Adultos >= 18 anos de idade no momento de assinatura do consentimento informado
    2. Possuir sintomas de bexiga hiperativa (BH) "húmida" (urgência, frequência e incontinência urinária) por >= 3 meses anteriores à visita de triagem
    3. Mulheres com potencial para engravidar (MPE) devem concordar em utilizar métodos contraceptivos aceitáveis e eficazes
    4. Ser capaz de dar o consentimento informado
    5. Disposto e capaz de completar o diário eletrónico da bexiga e os questionários

    Critérios de Inclusão na linha de base (a serem verificados na v3, antes da randomização):
    6. Conclusão de todos os 3 dias do diário eletrónico da bexiga-3 dias durante o periodo de pré-tratamento
    7. Conformidade >= 80% na toma da intervenção do estudo durante o período de pré-tratamento
    8. Frequência de micção em média >= 8 episódios / 24 horas durante a fase de pré-tratamento de acordo com o diário eletrónico da bexiga-3 dias
    9. Frequência de incontinência urinária de urgência em média >= 1 episódio / 24 horas durante a fase de pré-tratamento de acordo com o diário eletrónico da bexiga-3 dias
    E.4Principal exclusion criteria
    1. Polyuria known or based on the clinical evidence during the run-in phase recorded in the 3-day electronic bladder diary and the investigator´s clinical judgement
    2. Significant stress incontinence or mixed stress/urgency incontinence
    3. Post-void residual volume (PVR) > 150 mL at Visit 1 or at Visit 3
    4. In need of catheterization (indwelling or intermittent)
    5. Clinically significant urinary outflow obstruction
    6. Previous pelvic radiation, or previous or current malignant disease of pelvic organs
    7. Neurogenic bladder
    8. Bladder pain syndrome/interstitial cystitis
    9. Recurrent and/or symptomatic bladder stones
    10. Current symptomatic or recent (within 30 days prior to Visit 1), or recurrent (2 or more infections within 6 months, or > 3 infections within 12 months) urinary tract infection
    11. Unexplained macro- or micro-hematuria
    12. Diabetes insipidus
    13. Diabetes mellitus with inadequate glycemic control as indicated by HbA1C result of > 8% at screening
    14. Clinically significant cardiovascular or cerebrovascular disease
    15. Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure
    ≥ 100 mmHg
    16. Clinically significant abnormal electrocardiogram (ECG) at screening
    17. Moderate-to-severe hepatic impairment defined as Child-Pugh Class B or C
    18. Laboratory values outside the inclusion range (as specified in the laboratory manual and in the reports from the central laboratory) before start of study intervention, and considered clinically relevant
    19. At screening:
    - ALT above 2xULN OR
    - AST above 2xULN OR
    - total bilirubin greater than ULN OR
    - AP above 2x ULN OR
    - INR greater than ULN (unless on vitamin K antagonist treatment)
    OR
    - Positive hepatitis B virus surface antigen (HBsAg) OR
    - Positive hepatitis C virus antibodies (anti-HCV) and detection of
    mRNA (HCV-mRNA, only tested if hepatitis C virus antibodies were
    detected)
    20. Severe renal impairment as defined by estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2 calculated by Modification of Diet in Renal Disease (MDRD) formula
    21. Any other diseases or conditions that according to the investigator can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study intervention (e.g., excessively low body weight, Chronic bowel disease, Crohn’s disease and ulcerative colitis)
    22. Any severe or unstable diseases or medical conditions including psychiatric disorders that might interfere with the conduct of the study, or could jeopardize the safety of the participant, or the interpretation of the results
    23. History of major depression within 2 years prior to screening, or a history of other major psychiatric disorder at any time (e.g., schizophrenia, bipolar disorder)
    24. Concurrent malignancy or history of cancer (except for adequately treated basal cell or squamous cell carcinoma of the skin) within the last 5 years prior to screening
    25. Intake of prohibited medication due to potential drug-drug interaction Use of other treatments that might interfere with the conduct of the study or the interpretation of the results e.g.
    a) use of any drug treatment after start of study intervention intended for the OAB/UI symptoms other than the study intervention
    b) neuromodulation therapy and intravesical treatment – less than 12 months prior to screening or at any time during the study
    c) use of any treatment intended for other conditions but which can affect urinary bladder function during the study
    d) Non-drug treatment (e.g. physical treatment or acupuncture) – permitted only if initiated ≥4 weeks prior to Screening and planned to be continued during the study)
    1. Poliúria conhecida ou baseada na evidência clínica durante a fase de pré-tratamento registada no diário eletrónico da bexiga-3 dias e no julgamento clínico do investigador
    2. Incontinência de esforço significativa ou mistura de esforço/urgência de incontinência
    3. Volume médio de urina que permanece na bexiga após a evacuação > 150 ml na Visita 1 ou na Visita 3
    4. Necessidade de cateterismo (interior ou intermitente)
    5. Obstrução do fluxo urinário clinicamente significativa
    6. Radiação pélvica anterior, ou anterior ou atual doença maligna dos orgãos pélvicos
    7. Bexiga neurogénica
    8. Síndrome da dor na bexiga/cistite intersticial
    9. Pedras na bexiga recurrentes e/ou sintomáticas
    10. Infecções do trato urinário atuais ou recentes (durante 30 dias anteriores à Visita 1) ou recorrentes (2 ou mais infecções em 6 meses, ou > 3 infecções durante 12 meses)
    11. Macro ou micro-hematúria sem explicação
    12. Diabetes insipidus
    13. Diabetes mellitus com controlo de glicémia inadequado conforme indicado nos resultados de HbA1C>8% na triagem
    14. Doença cardiovascular ou cérebro-vascular clinicamente significativa
    15. Pressão arterial sistólica ≥ 160 mmHg e/ou pressão arterial diastólica ≥ 100 mmHg
    16. Eletrocardiograma (ECG) anormal clinicamente significativo na triagem
    17. Insuficiência hepática moderada a grave definida como Child-Pugh classe B ou C
    18. Valores laboratoriais fora da faixa de inclusão (como especificado no manual de laboratório e nos relatórios do laboratório central) antes do início da intervenção do estudo, e considerados clinicamente relevantes
    19. Na triagem:
    - ALT acima 2xULN ou
    - AST acima 2xULN ou
    - bilirrubina total maior que ULN ou
    - AP acima 2xULN ou
    - INR maior que ULN (a menos que em tratamento com antagonista da vitamina k)
    OU
    - Antigénio de superfície do vírus da hepatite B positivo (HBsAg) OU
    - Anticorpos positivos para o vírus da hepatite C (anti-VHC) e detecção de mRNA (VHC-mRNA, testado apenas se os anticorpos do vírus da hepatite C forem detectados)
    20. Insuficiência renal grave conforme definido pela estimativa da taxa de filtração glomerular (eGRF) < 30 ml/min/1.72 m2 calculada pela fórmula (MDRD) de modificação da dieta na doença renal
    21. Qualquer outra doença ou condição que de acordo com o investigador possa comprometer a função dos sistemas do corpo e possa resultar numa absorção alterada, acumulação excessiva, metabolismo prejudicado, ou excreção alterada da intervenção do estudo (ex. peso corporal excessivamente baixo, doença intestinal crónica, doença de Chron ou colite ulcerosa)
    22. Qualquer doença severa ou instável ou condição médica incluíndo desordens psiquiátricas que possam interferir com a condução do estudo, ou possam comprometer a segurança do participante, ou a interpretação dos resultados
    23. Historial de depressão severa nos 2 anos anteriores à triagem, ou historial de outras desordens psiquiátricas severas em qualquer altura (e.x esquizofrenia, transtorno bipolar)
    24. Malignidade atual ou historial de cancro (excepto para carcinoma celular basal ou escamoso da pele adequadamente tratado) durante os 5 anos anteriores à triagem
    25. Toma de medicação proíbida devido a potencial de interação entre medicamentos na utilização de outros tratamentos que possam interferir com a condução do ensaio e interpretação dos resultados e.x.
    a) utilização de qualquer medicação de tratamento após o inicio da intervenção do estudo pretendido para os sintomas de BH/UI outros que não os da intervenção do estudo
    b) terapia de neuromodulação e tratamento intravesical - menos de 12 meses antes da triagem ou em qualquer momento durante o estudo
    c) uso de qualquer tratamento destinado a outra condição, mas que possa afetar a função da bexiga urinária durante o estudo
    d) tratamento não-medicamentoso (e.x tratamento físico ou acupuntura) - permitido apenas se iniciado >= 4 semanas antes da triagem e planeado para ser continuado durante o ensaio)
    E.5 End points
    E.5.1Primary end point(s)
    Average change from baseline over Week 4, 8 and 12 (end of treatment [EoT]) in mean number of urgency urinary incontinence (UUI) episodes/24 hours based on electronic bladder diary
    Alteração média face ao valor inicial do número médio de episódios de incontinência urinária de urgência (IUU)/24 h nas semanas 4, 8 e 12 (final do tratamento [FT]), com base num diário eletrónico da atividade da bexiga
    E.5.1.1Timepoint(s) of evaluation of this end point
    From baseline up to 12 weeks
    Do valor inicial até 12 semanas
    E.5.2Secondary end point(s)
    1. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of Urgency urinary incontinence (UUI) episodes/24 hours
    2. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of Urinary incontinence (UI) episodes/24 hours
    3. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of micturition episodes/24 hours
    4. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of urgency episodes (Grade 3 or 4)/24 hours
    5. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean number of nocturia episodes/24 hours
    6. Change from baseline to Week 12 (EoT) based on electronic bladder diary in mean volume voided per micturition
    7. The incidence of adverse events, drug-related adverse events and taste related adverse events
    8. The maximum intensity of adverse events per participant
    1. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do número médio de episódios de incontinência urinária de urgência IUU/24 h
    2. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do número médio de episódios de incontinência urinária IU/24 h
    3. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do número médio de episódios de micção/24 h
    4. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do número médio de episódios de urgência (Grau 3 ou 4)/24 h
    5. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do número médio de episódios de nictúria/24 h
    6. Alteração entre o valor inicial e o valor na semana 12 (FT) com base num diário eletrónico da atividade da bexiga do volume médio de urina evacuada por micção
    7. Incidência de eventos adversos, eventos adversos relacionados com a medicação e eventos adversos relacionados com o paladar
    8. Intensidade máxima de eventos adversos por participante
    E.5.2.1Timepoint(s) of evaluation of this end point
    1-6: From baseline up to 12 weeks
    7-8: From the start of study intervention (at start of run-in) until the follow-up visit (up to 18 weeks).
    1-6: Da avaliação inicial até às 12 semanas
    7-8: Do início da intervenção do estudo (no inicio do período de tratamento) até à visita de seguimento (até 18 semanas)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    UVUP (Última Visita do Último Participante)
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months5
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months5
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 70
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 30
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state20
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 100
    F.4.2.2In the whole clinical trial 100
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    none
    nenhum
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-06-23
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-06-15
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2022-01-21
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA